In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Bamforth, Entrepreneur, Mentor and Investor in life sciences.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering:
Mark’s backstory from oil barrels to brewing, to a small biotech called... Genzyme
A baptism of fire of having to raise money for a self-funded CDMO carve-out after 22 years in the corporate world
How a merger strategy led to the sale of Gallus BioPharmaceuticals to Patheon
Entering the viral vector space, and the story of Brammer Bio from start-up to a $1.7bn exit to Thermo

Mark founded, built, and sold three CDMOs over a period of 12 years. Gallus Biopharmaceuticals was focused on monoclonal antibodies, Brammer Bio produced viral vectors for gene therapy and Arranta Bio produced microbiome, plasmid and mRNA vaccines. In total, over 1,200 jobs were created and over 100 client clinical trial projects were enabled.
Prior to this, Mark previously spent 22 years at Genzyme, latterly running the 12-site global manufacturing operation and a pharmaceutical CMO business. He began his career as a petroleum engineer with Britoil, then as a chemical engineer with Whitbread.
He serves on the boards of Continuus Pharma, Pneumagen, Enterobiotix, Inceptor Bio, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.